❌

Reading view

There are new articles available, click to refresh the page.

A Parachute for Your ADHD Medication Crash

It’s 4 p.m. and your brain is suddenly caught in a riptide. You feel like a swimmer fighting a strong current. The focus, priorities, and momentum that have propelled you forward until now are submerged under a layer of brain fog that rolls in around the same time each day.

This phenomenon is called the ADHD medication crash, and it happens to two-thirds of ADDitude readers who take ADHD medication. When medication levels drop rapidly in the bloodstream, this can result in fatigue, slowed processing speed, and inertia.

Who Is Crashing?

According to 3,500 ADDitude survey responses, 57 to 78 percent of stimulant medication users experience a regular crash, with dextroamphetamine and Ritalin LA users reporting the highest prevalence. Even people taking the most popular stimulant medications reported crash prevalence rates of near or above 60 percent. (Users’ experiences with the most popular stimulant medications are shown in the chart below.) The lowest crash prevalence rates were reported by people taking the non-stimulant medications Atomoxetine/Strattera (40%) and guanfacine (52.9%), suggesting that medication crashes are less common with non-stimulant ADHD treatments.

Most Commonly
Used Medications
Respondents
Using It
Hours of
Coverage
Crash
Prevalence
Vyvanse 17.9% 7.9 59.3%
Adderall XR 9.2% 7.4 60.2%
Lisdexamfetamine (generic) 9.0% 8 59.9%
Adderall 8.8% 4.6 67.8%
Amphetamine/dextroamphetamine (generic) 8.7% 5 69.2%
Methylphenidate (generic) 8.5% 6 63.1%
Concerta 5.8% 8.5 60.1%

What Does the Crash Look Like?

The most common signs of a medication crash, according to ADDitude readers who experience them, include:

  • Difficulty starting tasks/inertia: 71.8%
  • Increased distractibility: 61.4%
  • Sudden tiredness/sleepiness: 53.8%
  • Trouble focusing/brain fog: 50.1%
  • Slowed processing: 45.6%
  • Irritability/short temper: 39.4%
  • Physical fatigue/heavy limbs: 36.7%

[Get This Free Download: ADHD Treatment Guide for Adults]

What Contributes to the Crash?

The odds of a medication crash increase when an individual is experiencing stress, inadequate sleep, poor diet, and lack of exercise, according to survey respondents. Almost two-thirds of women who experience crashes said their menstrual cycle impacts the crash symptom severity. Readers did not cite medication interactions or caffeine as significant contributors.

What Is Compromised During the Crash?

The ability to manage household responsibilities is “often” or “always” impaired by medication crashes for 70 percent of survey respondents. Half of crashers say work responsibilities “often” or “always” suffer, and 43 percent say social and family interactions suffer.

Can the Crash Be Softened?

More than two-thirds of ADDitude readers experience some kind of medication crash, even after discussing possible solutions with their medical providers. While there don’t appear to be any easy, universal fixes for crashes, readers cited the following medication strategies as helpful:

  • Adding an afternoon booster or immediate-release dose
  • Changing the timing of dosing
  • Switching to a longer-acting formulation
  • Switching to a non-stimulant

Non-medication strategies with the best results include:

  • Exercising or moving around
  • Delaying or rescheduling tasks
  • Taking a nap or resting
  • Eating a snack or a meal
  • Drinking caffeine

ADHD Medication Crash: Next Steps

Anni Layne Rodgers is General Manager at ADDitude.


ADDITUDE IS HUMAN
Artificial intelligence does not create or edit any written content published by ADDitude. Our editorial team is 100% human, and our mission is simple: listen to and serve our readers with hand-crafted, expert-informed resources. To support ADDitude, please consider subscribing. Your readership and support help make our commitment possible. Thank you.

“Is Generic ADHD Medication Less Effective Than the Brand-Name Version?”

Q: “My insurer stopped covering my brand-name ADHD medication, so I had to switch to the generic version. It doesn’t seem to be as effective. Could I be imagining this?”


The U.S. Food and Drug Administration (FDA) requires that generic and brand-name medication be roughly comparable regarding peak blood level and the total amount absorbed. But “roughly comparable” means that the level of the active ingredient(s) in a generic can range from 80% to 125% of that in the brand-name medication, so there is variability.

With higher-dose stimulants, especially, patient response hinges on the concentration of dopamine or norepinephrine delivered at the synapse, as well as the speed at which that dosage changes from one minute to the next. If you have a generic drug that is absorbed a little slower or faster, it can feel different.

[Download: The Soaring Cost of ADHD Care]

Your doctor, if they are willing, can petition your insurer by saying that the generic hasn’t worked for you and that you need the brand name of a certain drug. Sometimes, the pharmacy isn’t particularly willing to cooperate, even though they are allowed to. In those cases, there can be pushback from the pharmacy and/or more delays with each refill.

Still, this approach is at least an option for people who have noted clear and consistent differences between their generic and brand-name medications.

Generic ADHD Medications: Next Steps

John Kruse, M.D., Ph.D., is the author of Recognizing Adult ADHD. (#CommissionsEarned)


ADDITUDE IS HUMAN
Artificial intelligence does not create or edit any written content published by ADDitude. Our editorial team is 100% human, and our mission is simple: listen to and serve our readers with hand-crafted, expert-informed resources. To support ADDitude, please consider subscribing. Your readership and support help make our commitment possible. Thank you.

New Insight Into ADHD Stimulants: Optimal Doses by Age, Deprescribing Guidance

June 25, 2026

Less than one-third of people with ADHD find effective, efficient symptom relief with the first medication they try. According to a 2023 survey, ADDitude readers try 2.6 medications, on average, before settling on one and getting to work finding a dosage ‘sweet spot’ that balances efficacy against side effects. It’s an arduous process of trial-and-error that may benefit from new research on optimal dosing of ADHD medication by patient age.

According to a recent study of more than 25,000 individuals with ADHD aged 5 years and older, the optimal dose of medication varies by drug type and across age groups.1

Published in The Lancet Psychiatry, the systematic review of 164 studies and dose–effect network meta-analysis of 113 double-blind randomized controlled trials identified the most effective dose thresholds for several ADHD medications.

In children and adolescents with ADHD:

  • Methylphenidate (brand name: Ritalin) reached peak efficacy at approximately 45 mg/day.
  • Amphetamines (brand name: Adderall) reached peak efficacy at approximately 25 mg/day.
  • Lisdexamfetamine (brand name: Vyvanse) reached peak efficacy at approximately 55 mg/day.
  • Guanfacine (brand name: Intuniv) reached peak efficacy at approximately 4 mg/day.

In adults with ADHD:

  • Amphetamines reached peak efficacy at approximately 50 mg/day.
  • Methylphenidate efficacy increased without evidence of a plateau.

The U.K. research team, led by Samuele Cortese, M.D., Ph.D., of the National Institute for Health and Care Research (NIHR), found no evidence that exceeding FDA-licensed maximum doses improved any drug’s overall efficacy for any age group. The researchers did acknowledge, however, that some individuals with ADHD do require higher-than-licensed doses of medication.

They also found an association between medication discontinuation and doses at or slightly above peak efficacy. For example, the risk of medication discontinuation increased when amphetamine doses were above 25 mg/day for children and adolescents, and 50 mg/day for adults.

Among adults with ADHD, methylphenidate discontinuation risk increased when doses rose above 50 mg/day. However, taking higher doses of methylphenidate did not increase the likelihood that children or adolescents would stop taking the drug due to side effects.

The researchers emphasized that the study’s results are population-level benchmarks and not prescriptive recommendations.

“Our results are valid at the group level but cannot inform decision-making at the individual level,” they wrote. “Our evidence needs to be complemented by personalized considerations for each patient, with cautious dose titration, as well as implementation of a broader multimodal approach to improve both effectiveness and tolerability of ADHD treatment, ideally in a shared decision-making process.”

If a patient, particularly a child or adolescent, does not experience symptom benefit from an ADHD medication, clinicians are encouraged to titrate up from the minimum dose.

“Evidence from real-world studies shows that a substantial proportion of children and adolescents receive low doses of medication without appropriate upward titration,” the researchers wrote. “This is particularly concerning, as timely and adequate dose adjustment has been associated with improved adherence, probably by facilitating earlier symptom improvement and reinforcing engagement with treatment.”2, 3

Stimulants are considered the first-line treatment for ADHD, but not all children and adults respond to or tolerate stimulant medications; others may prefer to take a non-stimulant. According to the ADDitude treatment survey of more than 11,000 adults and caregivers:

  • 52% of children taking medication for ADHD use methylphenidate, and their caregivers rate it an average of 3.15 out of 5 for efficacy
  • 34% take a form of amphetamine, and their caregivers rated it an average of 2.97 out of 5
  • 16% of children treat their ADHD with non-stimulants, and their caregivers rate it an average of 2.45 out of 5 for efficacy

Among adults taking ADHD medication:

  • 63% use a form of amphetamine, and they rated it an average of 3.31 out of 5 for efficacy
  • 29% use a form of methylphenidate, and they rate it an average of 2.8 out of 5 for efficacy
  • 8% use a non-stimulant, and they rate it an average of 2.3 out of 5 for efficacy

“Gauging whether a medication is working as well as it should, or whether it’s the right medication at all, requires consistent self-appraisal and ongoing communication with your clinician regarding symptom control — or lack thereof,” said William Dodson, M.D., LF-APA, in the ADDitude webinar “Optimizing ADHD Medication: Strategies for Achieving Better Symptom Management.” “It also requires patience as the clinician works to potentially adjust or switch medications before settling on the right combination.”

A new consensus statement developed by the American Society of Clinical Psychopharmacology (ASCP) aims to support clinicians in determining when stimulants are an appropriate treatment and when they should be reconsidered.4

The first-ever formal guidelines identified clinical scenarios for deprescribing stimulant medications in adults with ADHD, including when:

  • A patient is misdiagnosed with ADHD.
  • A patient receives no benefit from the medication.
  • A patient develops tolerance for the medication.
  • Stimulants exacerbate a patient’s co-occurring condition(s).
  • Side effects cannot be managed by reducing the dose of the stimulants.
  • A change in medical status shifts the risk-benefit ratio.
  • A patient persistently exceeds their prescribed dose.
  • A patient diverts their medication to others.
  • A patient uses their medication for enhancement beyond ADHD treatment.

To reach a consensus, at least 75% of the panelists needed to “strongly agree” or “moderately agree” with each statement. The one statement that did not reach a consensus involved cannabis use; 71% of panelists felt that regular cannabis use was an insufficient reason to deprescribe stimulant medication in adults with ADHD.

The guidelines do not provide specific medication tapering schedules, but they do recommend a gradual, personalized taper that emphasizes “sleep hygiene, physical activity, and structured behavioral strategies that support executive functioning.”

Findings from The Lancet Psychiatry study and the consensus statement could inform the forthcoming adult ADHD clinical practice guidelines from the American Professional Society of ADHD and Related Disorders (APSARD), expected later this year.

Sources

1 Nourredine, M., Jurek, L., Hamza, T. et al. (2026). Pharmacological interventions for ADHD: a systematic review and dose–effect network meta-analysis. The Lancet Psychiatry. https://doi.org/10.1016/j.euroneuro.2026.112863

2 Olfson, M., Marcus, S., Wan, G. (2009). Stimulant dosing for children with ADHD: a medical claims analysis. J Am Acad Child Adolesc Psychiatry. https://doi.org/10.1097/CHI.0b013e31818b1c8f

3 Xu, Y., Chung, H., Shu, M., et al. (2023). Dose titration of osmotic release oral system methylphenidate in children and adolescents with attention-deficit hyperactivity disorder: a retrospective cohort study. BMC Pediatr. https://doi.org/10.1186/s12887-023-03850-4

4 Goodman, D., Mago, R., Citrome, L., Swartz, H.A., McIntyre, R.S., et al. (2026). The American Society of Clinical Psychopharmacology task force consensus statement on the deprescribing of stimulant medications in adults with ADHD. European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2026.112863

❌